Arrhythmia Research Technology, Inc.  

(Public, NYSEMKT:HRT)   Watch this stock  
Find more results for NYSEAMEX:HRT
-0.16 (-2.51%)
May 22 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 6.22 - 6.38
52 week 5.50 - 8.00
Open 6.28
Vol / Avg. 626.00/5,250.00
Mkt cap 17.29M
P/E 115.55
Div/yield     -
EPS 0.05
Shares 2.78M
Beta 1.20
Inst. own 14%
May 13, 2015
Q1 2015 Arrhythmia Research Technology Inc Earnings Release
Mar 20, 2015
Q4 2014 Arrhythmia Research Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -4.35% 2.75%
Operating margin -3.45% 3.70%
EBITD margin - 10.10%
Return on average assets -6.66% 4.20%
Return on average equity -14.02% 9.73%
Employees 98 -
CDP Score - -


25 Sawyer Passway
United States - Map
+1-978-3455000 (Phone)
+1-978-3420168 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arrhythmia Research Technology, Inc. (ART) manufactures components, devices and equipment for medical, military, law enforcement, industrial and automotive applications. The Company is engaged in the production and sale of silver/silver chloride coated and conductive resin sensors used as component parts in the manufacture of integrated disposable electrophysiological sensors. The Company also performs custom thermoplastic injection molding and provides a full array of design, engineering and production services and management. The Company's orthopedic implant machining operation produces quick-turn, high volume and patient-specific, finished orthopedic implants. In addition to its manufacturing capabilities, the Company, through its Predictor brand, also licenses proprietary customizable signal-averaging electrocardiography (SAECG) software used to help assess a patient's risk of certain heart arrhythmias.

Officers and directors

E. P. Marinos Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Salvatore Emma Jr. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Derek T. Welch Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Robert A. Mello Director
Age: 61
Bio & Compensation  - Reuters
Jason R. Chambers Independent Director
Age: 37
Bio & Compensation  - Reuters
Paul F. Walter M.D. Independent Director
Age: 78
Bio & Compensation  - Reuters